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Simple Summary: International Working Group (IWG) and European LeukemiaNet (ELN) adult
response definitions are currently used to evaluate the efficacy of new agents for childhood acute
myeloid leukemia (AML); however, the criteria are not consistent with consensus definitions used
in pediatric trials or the common practice of intensifying treatment prior to full hematopoietic
recovery of ANC ≥ 1000 cells/µL and platelets ≥ 100 cells/µL. This retrospective analysis of the two
most recent Phase 3 AML trials in the Children’s Oncology Group assesses the incidence, timing,
and prognostic significance of count recovery following induction chemotherapy in children with
AML. These data confirm that awaiting count recovery to meet adult criteria does not reflect standard
practice in pediatric AML and IWG/ELN-defined CR does not have a significant impact on survival
in children. Continuing to use adult IWG/ELN count recovery definitions limits childhood AML
drug development by underestimating response, and therefore, updated response criteria are needed
for pediatric AML patients.
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Abstract: International Working Group (IWG) and European LeukemiaNet (ELN) response definitions are utilized to evaluate the efficacy of new agents for childhood acute myeloid leukemia
(AML) for regulatory purposes. However, these criteria are not consistent with definitions used in
pediatric AML trials or with standard pediatric practice to proceed with subsequent therapy cycles
prior to IWG/ELN-defined count recovery. We retrospectively analyzed data from the two most
recent Phase 3 pediatric AML clinical trials conducted by the Children’s Oncology Group (COG)
to assess the incidence, timing, and prognostic significance of count recovery following induction
chemotherapy. Of the patients with fewer than 5% bone marrow blasts at the end of first induction,
21.5% of patients proceeded to a second induction cycle prior to achieving ANC ≥ 500 cells/µL and
platelets ≥ 50,000 cells/µL, both well below the IWG/ELN thresholds of ANC > 1000 cells/µL and
platelets > 100,000 cells/µL. In these two sequential childhood AML Phase 3 trials, neither ANC nor
platelet recovery predicted survival. Intensification of treatment through the initiation of subsequent
therapy cycles prior to attainment of IWG/ELN-defined CR is common practice in clinical trials for
children with AML, suggesting that updated response definitions are needed for pediatric AML.
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1. Introduction
Acute myeloid leukemia (AML) in children and adults represent a phenotypically
heterogeneous and genetically complex subtype of hematopoietic malignancies. There are
approximately 20,000 newly diagnosed cases of AML in the United States each year with
an average age at diagnosis of 68 years; however, fewer than 500 of these cases occur in
children under the age of 15. Given this differential age distribution [1], clinicians have
long assumed that AML observed in older adults is distinct from that seen in children.
Age is not a defining characteristic of AML according to the World Health Organization
(WHO); rather, the category of AML with recurrent genetic abnormalities captures many
of the structural variants seen in more than 50% of children with AML and fewer than
15% of older adults [2–4]. Assessment of treatment response for children and adults
with AML in the United States is currently based on the International Working Group
(IWG) criteria, first published in 1990 [5] and updated in 2003 [6]. The IWG criteria
require a peripheral complete blood count (CBC) and histologic quantification of bone
marrow blasts by microscopy, and define complete response (CR) as fewer than 5% bone
marrow blasts with an absolute neutrophil count (ANC) > 1000 cells/µL and platelets (plt)
> 100,000 cells/µL. Similar criteria are followed by the European LeukemiaNet (ELN) in
adults with AML [7]. These response criteria have remained the standard by which the
efficacy of new drugs is measured in clinical trials in both adults and children.
In 2010, Walter et al. demonstrated clearly that in adult AML patients treated 15 to
35 years ago, it was routine to await count recovery at the end of induction to evaluate
for residual dysplasia [8]. During this 19-year study period, 97% of adult patients with
less than 5% blasts had platelet count recovery to greater than 100,000 cells/µL after initial
induction therapy, and count recovery was associated with improved survival. These data
support the IWG and ELN response criteria for AML in adults. Recognizing that these
criteria have never been validated in children, herein we assess the incidence of count
recovery and its prognostic impact on survival in children with AML treated in the most
recent AML trials from the Children’s Oncology Group (COG). We hypothesized that the
adult IWG/ELN criteria do not predict survival in pediatric patients.
2. Materials and Methods
2.1. Patients
We retrospectively analyzed data from the two most recent Phase 3 pediatric clinical trials for de novo AML conducted by the COG in the United States. The eligibility,
therapy, and results for these trials have been previously reported [9,10]. The CONSORT
diagrams describing patients analyzed in this dataset are included in Figure 1. Data from
the COG cohort include more than 2700 patients 1–29 years of age with AML diagnosed
between 2006 and 2018 and enrolled in AAML0531 (NCT00372593) [9] and AAML1031
(NCT01371981) [10]. Patients with Down syndrome AML (DS-AML) in AAML0531 (n = 6)
were excluded from this analysis, as were all patients enrolled in AAML1031’s Arm D expansion cohort (n = 378) because response data were not collected for these patients. Patients
who withdrew consent or went off-study for other reasons were censored at that date.

Cancers
Cancers2022,
2022,13,
14,x 616

3 of
1010
3 of

Figure
Figure1.1.CONSORT
CONSORTdiagram.
diagram.

Amongpatients
patientsenrolled
enrolledininboth
bothtrials,
trials,1861
1861(89.3%)
(89.3%)had
hadRD
RDassessed
assessedbybycentrally
centrally
Among
performeddifference-from-normal
difference-from-normal(ΔN)
(∆N)flow
flowcytometry
cytometryatatthe
theend
endofofinduction
inductionI, I,which
which
performed
waspreviously
previouslyshown
shown to
to be
response
in children
[11].
was
be superior
superior to
tomorphology
morphologyininassessing
assessing
response
in children
Those
with
<5%
RD
by
∆N
(n
=
1645)
achieved
a
complete
response
and
were
evaluated
[11]. Those with <5% RD by ΔN (n = 1645) achieved a complete response and were evalufor for
timetime
to and
incidence
of count
recovery.
Comprehensive
CBCCBC
datadata
were
not not
collected
ated
to and
incidence
of count
recovery.
Comprehensive
were
colfor
each
patient.
Instead,
investigators
were
required
to
report
whether
patients
achieved
lected for each patient. Instead, investigators were required to report whether patients
peripheral
ANC of 500
cells/µL
non-transfused
platelet count
of 50,000
cells/µL
prior
achieved
peripheral
ANC
of 500and
cells/μL
and non-transfused
platelet
count
of 50,000
to Induction
II, Induction
and the date
eachthe
parameter
was
achieved.was
Both
COG trials
recommended
cells/μL
prior to
II, and
date each
parameter
achieved.
Both
COG trials
but
did
not
require
that
Induction
II
begin
when
ANC
>
1000
cells/µL
and
platelets
recommended but did not require that Induction II begin when ANC > 1000 cells/μL
and
>
75,000
cells/µL
(Table
1).
Survival
analysis
based
on
count
recovery
group
was
perplatelets > 75,000 cells/μL (Table 1). Survival analysis based on count recovery group was
formed
using
disease-free
survival
(DFS)
and
overall
survival
(OS)
from
end
of
induction
performed using disease-free survival (DFS) and overall survival (OS) from end of inducI, and
excluded
the 60
in AAML1031
(Arm
C) who
received
sorafenib
for HAR
tion
I, and
excluded
thepatients
60 patients
in AAML1031
(Arm
C) who
received
sorafenib
for
FLT3-ITD
disease
(n
=
1585;
Figure
1).
HAR FLT3-ITD disease (n = 1585; Figure 1).
Table1.1.Count
Countrecommendations
recommendationsfor
forproceeding
proceedingwith
withthe
thenext
nextcycle
cycleofofchemotherapy.
chemotherapy.
Table
COG De
Novo Cohort
COG AML
COG De Novo
Cohort
CurrentCurrent
COG AML
StudyStudy
(AAML0531
and
AAML1031
*)
(AAML1831
*)
(AAML0531 and AAML1031 *)
(AAML1831 *)
>1000 cells/µL
>500 cells/µL
ANC ANC
>1000 cells/μL
>500 cells/μL
Platelets
>75,000 cells/μL
>50,000>50,000
cells/μL
Platelets
>75,000 cells/µL
cells/µL

IWG/ELN
IWG/ELN
>1000
cells/µL
>1000
cells/μL
>100,000
cells/μL
>100,000
cells/µL

Table
AAML0531
(NCT00372593),
AAML1031
(NCT01371981),
AAML1831
TableLegend:
Legend: ** AAML0531
(NCT00372593),
AAML1031
(NCT01371981),
AAML1831
(NCT04293562); Abbreviations: AML, acuteAbbreviations:
myeloid leukemia;
ANC,
absolute
neutrophil
count;ANC,
COG, absolute
Children’sneutrophil
Oncology Group;
(NCT04293562);
AML,
acute
myeloid
leukemia;
count;ELN,
European
LeukemiaNet;
IWG,Group;
International
Group.
COG,
Children’s
Oncology
ELN, Working
European
LeukemiaNet; IWG, International Working
Group.

Cancers 2022, 14, 616

4 of 10

2.2. Statistical Analysis
Statistical analyses were performed with SAS version 9.4 (SAS Institute Inc., Cary,
NC, USA). The Kaplan–Meier method was applied to estimate probabilities of survival
with standard errors according to Greenwood and compared with the log-rank test [12].
Survival curves were compared using the log-rank test and based on count recovery
(ANC ≥ 500 cells/µL only, platelets ≥ 50,000 cells/µL only, both ANC ≥ 500 cells/µL and
platelets ≥ 50,000 cells/µL, and neither ANC ≥ 500 cells/µL nor platelets ≥ 50,000 cells/µL).
OS was calculated from end of induction I to death of any cause, and DFS was defined as
time from end of induction I to treatment failure, relapse, secondary malignancy, or death.
Cumulative incidence functions of ANC/platelet recovery, relapse, or early death were
constructed according to Kalbfleisch and Prentice [13]. The Cox proportional hazards model
was used for multivariable analysis of outcomes [14]. For consistency in multivariable
survival analysis, COG risk groups for this analysis were defined by current COG Phase
3 (AAML1831, NCT04293562) cytomolecular risk stratification and MRD [15] rather than
original study-assigned risk group. Proportions were compared between groups using the
chi-square test or Fisher’s exact test when data were sparse. p values <0.05 were considered
significant. Living patients were censored at date of last follow-up. Data were frozen at 31
December 2019.
3. Results
3.1. Proportion of Patients with Count Recovery
Among all patients with fewer than 5% bone marrow AML blasts by centralized ∆N
flow cytometry (n = 1645), the proportion of patients who proceeded to Induction II prior
to recovery of ANC ≥ 500 cells/µL and platelet count ≥ 50,000 cells/µL was 21.5% (7.4%
with ANC only + 8.3% with platelets only + 5.8% with neither ANC nor platelet recovery;
Table 2).
Table 2. Count recovery following first induction on AAML0531 and AAML1031.
Patients with <5%
Marrow Disease by
∆N Flow Cytometry

ANC
Threshold
Only (>500/µL)

Platelet
Threshold
Only
(>50,000/µL)

Met Both
(ANC > 500/µL and
Plt > 50,000/µL)

Met Neither
(ANC ≤ 500/µL and
Plt ≤ 50,000/µL)

ANC and/or
Platelets Not
Evaluated during
Reporting Period

AAML0531

660

57 (8.6%)

55 (8.3%)

507 (76.8%)

41 (6.2%)

4 (0.6%)

AAML1031

985

65 (6.6%)

81 (8.2%)

785 (79.7%)

54 (5.5%)

1 (0.1%)

Combined

1645

122 (7.4%)

136 (8.3%)

1292 (78.5%)

95 (5.8%)

5 (0.3%)

Table abbreviations: ANC, absolute neutrophil count; ∆N, difference from normal; Plt, platelet.

In a cumulative incidence of count recovery analysis, 96.2% and 98.1% of patients
recovered ANC ≥ 500 cells/µL or platelet counts ≥ 50,000 cells/µL across the two Phase 3
COG trials at 42 and 49 days from the start of induction therapy, respectively. Only 86.3%
and 92.4% reported recovery of both ANC ≥ 500 cells/µL and platelets ≥ 50,000 cells/µL
at 42 and 49 days from the start of induction therapy, respectively (Figure 2). Additional
patient characteristics by count recovery group can be found in Supplemental Table S1.
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4.2. Count Recovery Does Not Significantly Impact Survival in These Large Pediatric Datasets
regeneration.
The current IWG/ELN criteria for response imply that the absence of full hematopoietic recovery (ANC > 1000 cells/uL and plt > 100 cells/uL) is prognostic in adults with
AML. Although retrospective studies have suggested inferior outcomes for adult patients
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with CRi/CRp compared to those with CR [8,18], this has never been validated in pediatric
AML patients. While our pediatric cohort is not adequately powered to specifically answer
this survival question, it represents the largest US dataset available to review incidence
and survival associated with count recovery, and the sample size is comparable to the
Walter cohort [8]. Our retrospective evaluation of the available COG de novo AML data
was unable to detect a significant difference in DFS and OS based on ANC and platelet
recovery in children (Figure 3). Likewise, recent BFM data also confirm that count recovery
does not predict survival in the setting of first relapse of AML [19,20]. Although in Figure 3
the DFS and OS appear lower in the COG cohort without ANC or platelet recovery by
the end of induction I, this trend was not statistically significant. We do note that the
number of patients with EOI1 MRD positivity, a known prognostic factor, was higher in
the cohort without ANC and platelet recovery when compared to other cohorts (p = 0.063)
(Supplemental Table S1). Survival in all COG cohort groups was comparable until two
years of follow-up, after which six patients in AAML0531 experienced late relapses. MRD
rates were similar between these late relapse patients and the rest of the cohorts.
One of the limitations of this study is the lack of detailed end-of-induction CBC data
for each patient enrolled in these clinical trials. Therefore, we are unable to directly refute the IWG/ELN CR criteria (ANC ≥ 1000 cells/µL and platelets ≥ 100,000 cells/µL).
As described above, it is not common practice for physicians treating childhood AML to
wait for count recovery to these thresholds, and therefore, cut-offs of ANC ≥ 500 of cells/µL
and platelets ≥ 50,000 cells/µL were used for data analysis. Data from our colleagues in
the International Berlin-Frankfurt-Munster (i-BFM) group confirm this practice, demonstrating that only one-third of patients achieve recovery to IWG/ELN criteria after AML
induction (personal communication, Dirk Rheinhardt). It is possible that strict adherence to
waiting for count recovery to the IWG/ELN criteria might show more significant survival
differences among these groups.
4.3. Cheson Criteria Should Be Reconsidered as the Standard Response Evaluation in Children with
AML, and Perhaps Also in Adults
The current IWG and ELN criteria were based upon retrospective data in adults
supporting prolonged survival for patients who achieve CR [8]. Specifically, Walter et al.
demonstrated that among 1321 patients treated between 1984 and 2004, CR was independently associated with a longer relapse-free survival relative to CRp [8]. In comparison
to the COG experience, the Walter et al. data demonstrate clear differences in tolerance
for waiting for full count recovery that may be influenced by the underlying biology of
adult AML compared to childhood AML. Despite this, CR by IWG/ELN criteria are the
standard applied by regulatory authorities to new drug approvals in children. The Food
and Drug Administration goes so far as to define a treatment failure as a failure to achieve
CR by IWG criteria [21]. As we consider how best to assess response in children with
AML, we must consider that the standards of care for children and adults captured in
this dataset are clearly and substantially different. Therefore, using the IWG/ELN criteria
risks an underestimate of response in children, even if CRp is included in the overall
response assessment.
Although CR per IWG and ELN criteria has historically been used as a surrogate for
survival in adults, recent studies question the reliable association between CR and survival,
suggesting it may be time to reconsider these definitions for response evaluation in both
adult and pediatric AML [22]. Multiple recent adult studies have demonstrated significant
improvements in CR rates without improvement in survival [23,24], inferior CR rates with
comparable survival [25,26], and absence of CR with improved survival [27]. These data
suggest that response, as currently defined by the IWG/ELN, may over- or underestimate
survival in adults with AML treated with contemporary therapies.
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5. Conclusions
In the largest available US pediatric cohort, we are unable to confirm an association
between peripheral blood count recovery and survival, despite a comparable sample size to
the Walter et al. cohort. Continuing to use adult IWG/ELN response assessment definitions
places severe limitations on childhood AML drug development by classifying lack of CR
using these guidelines as treatment failure. Additionally, these definitions are not aligned
with the standard of care for intensification of pediatric AML therapy and are not followed
by pediatric oncologists.
Given the data presented here, response criteria must be reconsidered for pediatric
patients with AML. International cooperative groups are currently working to compile new,
standard definitions for both count recovery thresholds and remission status in order to
more accurately define treatment responses in future pediatric AML trials. In the meantime,
we propose that CR, CRp and CRi are all valid primary study endpoints.
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Author Contributions: Conceptualization, T.M.C. and E.A.K.; methodology, T.M.C., E.A.K. and
T.A.A.; formal analysis, R.B.G. and T.A.A.; writing—original draft preparation, L.P., T.M.C. and
E.A.K.; writing—review and editing, L.B., M.L., A.G., R.A., T.A.A. and R.B.G. All authors have read
and agreed to the published version of the manuscript.
Funding: Supported by St. Baldrick’s Foundation, the Leukemia and Lymphoma Society Children’s Initiative (TMC, EAK), the Leukemia Research Foundation of Delaware (EAK), the National
Cancer Institution of the National Institutes of Health National Clinical Trials Network (NCTN)
Operations Center grant U10CA180886, NCTN Statistics & Data Center Grant U10CA180899 (TAA),
the Children’s Oncology Group Chair’s Grant U10CA098543, and the Statistics and Data Center
Grant U10CA098413.
Institutional Review Board Statement: The retrospective analysis and all included studies were performed in accordance with the Declaration of Helsinki. AAML0531 and AAML1031 were conducted
by the Children’s Oncology Group. Each study was approved by the Pediatric Central Institutional
Review Board at the National Cancer Institute in compliance with the United States Code of Federal
Regulations and by appropriate ethics authorities at each participating COG member site.
Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.
Data Availability Statement: The Children’s Oncology Group Data Sharing policy describes the
release and use of COG individual subject data for use in research projects in accordance with
National Clinical Trials Network (NCTN) Program and NCI Community Oncology Research Program
(NCORP) Guidelines. Only data expressly released from the oversight of the relevant COG Data
and Safety Monitoring Committee (DSMC) are available to be shared. Data sharing will ordinarily
be considered only after the primary study manuscript is accepted for publication. For phase 3
studies, individual-level de-identified datasets that would be sufficient to reproduce results provided
in a publication containing the primary study analysis can be requested from the NCTN/NCORP
Data Archive at https://nctn-data-archive.nci.nih.gov/, accessed on 22 November 2021. Data
are available to researchers who wish to analyze the data in secondary studies to enhance the
public health benefit of the original work and agree to the terms and conditions of use. For nonphase 3 studies, data are available following the primary publication. An individual-level deidentified dataset containing the variables analyzed in the primary results paper can be expected
to be available upon request. Requests for access to COG protocol research data should be sent to:
datarequest@childrensoncologygroup.org. Data are available to researchers whose proposed analysis
is found by COG to be feasible and of scientific merit and who agree to the terms and conditions of
use. For all requests, no other study documents, including the protocol, will be made available and no
end date exists for requests. In addition to above, release of data collected in a clinical trial conducted
under a binding collaborative agreement between COG or the NCI Cancer Therapy Evaluation

Cancers 2022, 14, 616

9 of 10

Program (CTEP) and a pharmaceutical/biotechnology company must comply with the data sharing
terms of the binding collaborative/contractual agreement and must receive the proper approvals.
Acknowledgments: To Dirk Reinhardt for his review of the data and discussion of the key issues.
Conflicts of Interest: Michael Loken and Lisa Brodersen are both employed and have equity ownership in Hematologics, Inc. The other authors declare no conflict of interest.

References
1.
2.

3.

4.

5.

6.

7.

8.

9.

10.

11.

12.
13.
14.
15.

16.

17.

18.

Puumala, S.E.; Ross, J.A.; Aplenc, R.; Spector, L. Epidemiology of childhood acute myeloid leukemia. Pediatr. Blood Cancer 2013,
60, 728–733. [CrossRef] [PubMed]
Arber, D.A.; Orazi, A.; Hasserjian, R.; Thiele, J.; Borowitz, M.J.; Le Beau, M.M.; Bloomfied, C.D.; Cazzola, M.; Vardiman, J.W.
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016, 127,
2391–2405. [CrossRef] [PubMed]
Bolouri, H.; Farrar, J.E.; Triche, T., Jr.; Ries, R.E.; Lim, E.L.; Alonzo, T.A.; Ma, Y.; Moore, R.; Mungal, A.J.; Marra, M.A.; et al.
The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational
interactions. Nat. Med. 2018, 24, 103–112. [CrossRef] [PubMed]
Tarlock, K.; Zhong, S.; He, Y.; Ries, R.; Severson, E.; Bailey, M.; Morley, S.; Balasubramanian, S.; Erlich, R.; Lipson, D.; et al. Distinct
age-associated molecular profiles in acute myeloid leukemia defined by comprehensive clinical genomic profiling. Oncotarget
2018, 9, 26417–26430. [CrossRef]
Cheson, B.D.; Cassileth, P.A.; Head, D.R.; Schiffer, C.A.; Bennett, J.M.; Bloomfield, C.D.; Brunning, R.; Gale, R.P.; Grever, M.R.;
Keating, M.J. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute
myeloid leukemia. J. Clin. Oncol. 1990, 8, 813–819. [CrossRef]
Cheson, B.D.; Bennett, J.M.; Kopecky, K.J.; Büchner, T.; Willman, C.L.; Estey, E.H.; Schiffer, C.A.; Doehner, H.; Tallman, M.S.;
Lister, T.A.; et al. Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response
Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J. Clin. Oncol. 2003,
21, 4642–4649. [CrossRef]
Döhner, H.; Estey, E.H.; Amadori, S.; Appelbaum, F.R.; Büchner, T.; Burnett, A.K.; Dombret, H.; Fenaux, P.; Grimwade, D.;
Larson, R.A.; et al. Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international
expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115, 453–474. [CrossRef]
Walter, R.B.; Kantarjian, H.M.; Huang, X.; Pierce, S.A.; Sun, Z.; Gundacker, H.M.; Ravandi, F.; Faderl, S.H.; Tallman, M.S.;
Appelbaum, F.R.; et al. Effect of Complete Remission and Responses Less Than Complete Remission on Survival in Acute
Myeloid Leukemia: A Combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer
Center Study. J. Clin. Oncol. 2010, 28, 1766–1771. [CrossRef]
Gamis, A.S.; Alonzo, T.A.; Meshinchi, S.; Sung, L.; Gerbing, R.B.; Raimondi, S.C.; Hirsch, B.A.; Kahwash, S.B.; Winter, L.; Glick, K.
Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by
reducing relapse risk: Results from the randomized phase III Children’s Oncology Group trial AAML. J. Clin. Oncol. 2014, 32,
3021–3032. [CrossRef]
Aplenc, R.; Meshinchi, S.; Sung, L.; Alonzo, T.; Choi, J.; Fisher, B.; Gerbing, R.; Hirsch, B.; Horton, T.; Kahwash, S.; et al. Bortezomib
with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: A report from the
Children’s Oncology Group. Haematologica 2020, 105, 1879–1886. [CrossRef]
Brodersen, L.E.; Gerbing, R.B.; Pardo, M.L.; Alonzo, T.A.; Paine, D.; Fritschle, W.; Hsu, F.-C.; Pollard, J.A.; Aplenc, R.;
Kahwash, S.B.; et al. Morphologic remission status is limited compared to DeltaN flow cytometry: A Children’s Oncology
Group AAML0531 report. Blood Adv. 2020, 4, 5050–5061. [CrossRef] [PubMed]
Kaplan, E.L.; Meier, P. Nonparametric Estimation from Incomplete Observations. J. Am. Stat. Assoc. 1958, 53, 457. [CrossRef]
Kalbfleisch, J.; Prentice, R. The Statistical Analysis of Failure Time Data; John Wiley: New York, NY, USA, 1980.
Cox, D.R. Regression Models and Life-Tables. Breakthr. Stat. 1992, 527–541. [CrossRef]
Cooper, T.M.; Ries, R.E.; Alonzo, T.A.; Gerbing, R.B.; Loken, M.R.; Brodersen, L.E.; Raimondi, S.C.; Hirsch, B.A.; Aplenc, R.;
Gamis, A.S.; et al. Revised Risk Stratification Criteria for Children with Newly Diagnosed Acute Myeloid Leukemia: A Report
from the Children’s Oncology Group. Blood 2017, 130, 407.
Lange, B.J.; Smith, F.O.; Feusner, J.; Barnard, D.R.; Dinndorf, P.; Feig, S.; Heerema, N.A.; Arndt, C.; Arceci, R.J.; Seibel, N.; et al.
Outcomes in CCG-2961, a children’s oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: A report from
the children’s oncology group. Blood 2008, 111, 1044–1053. [CrossRef] [PubMed]
Abrahamsson, J.; Forestier, E.; Heldrup, J.; Jahnukainen, K.; Jónsson, G.; Lausen, B.; Palle, J.; Zeller, B.; Hasle, H. Response-Guided
Induction Therapy in Pediatric Acute Myeloid Leukemia with Excellent Remission Rate. J. Clin. Oncol. 2011, 29, 310–315.
[CrossRef] [PubMed]
Chen, X.; Xie, H.; Wood, B.L.; Walter, R.; Pagel, J.M.; Becker, P.S.; Sandhu, V.K.; Abkowitz, J.L.; Appelbaum, F.R.; Estey, E.H.
Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact on Outcome in Acute Myeloid Leukemia.
J. Clin. Oncol. 2015, 33, 1258–1264. [CrossRef]

Cancers 2022, 14, 616

19.

20.

21.

22.
23.

24.

25.

26.

27.

10 of 10

Kaspers, G.J.L.; Zimmermann, M.; Reinhardt, D.; Gibson, B.E.S.; Tamminga, R.Y.J.; Aleinikova, O.; Armendariz, H.; Dworzak, M.;
Ha, S.-Y.; Hasle, H.; et al. Improved Outcome in Pediatric Relapsed Acute Myeloid Leukemia: Results of a Randomized Trial on
Liposomal Daunorubicin by the International BFM Study Group. J. Clin. Oncol. 2013, 31, 599–607. [CrossRef]
Rasche, M.; Zimmermann, M.; Steidel, E.; Alonzo, T.; Aplenc, R.; Bourquin, J.-P.; Boztug, H.; Cooper, T.; Gamis, A.; Gerbing, R.;
et al. Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG. Cancers 2021,
13, 2336. [CrossRef]
U.S. Department of Health and Human Services Food and Drug Administrations. Acute Myeloid Leukemia: Developing Drugs
and Biological Products for Treatment; Guidance for Industry. August 2020. Available online: https://www.fda.gov/media/1408
21/download (accessed on 22 September 2021).
Bloomfield, C.D.; Estey, E.; Pleyer, L.; Schuh, A.C.; Stein, E.M.; Tallman, M.S.; Wei, A. Time to repeal and replace response criteria
for acute myeloid leukemia? Blood Rev. 2018, 32, 416–425. [CrossRef]
Burnett, A.K.; Hills, R.K.; Hunter, A.E.; Milligan, D.; Kell, W.J.; Wheatley, K.; Yin, J.; McMullin, M.F.; Dignum, H.; Bowen, D.; et al.
The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival
in older patients with acute myeloid leukaemia: Results from the LRF AML14 and NCRI AML16 pick-a-winner comparison.
Leukemia 2013, 27, 75–81. [CrossRef] [PubMed]
Burnett, A.K.; Russell, N.H.; Hunter, A.E.; Milligan, D.; Knapper, S.; Wheatley, K.; Yin, J.; McMullin, M.F.; Ali, S.; Bowen, D.; et al.
Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood 2013,
122, 1384–1394. [CrossRef] [PubMed]
van der Helm, L.H.; Scheepers, E.R.; Veeger, N.J.; Daenen, S.M.; Mulder, A.B.; van den Berg, E.; Vellenga, E.; Huls, G. Azacitidine
might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: A single centre retrospective
study of 227 consecutive patients. J. Hematol. Oncol. 2013, 6, 29. [CrossRef] [PubMed]
Gupta, N.; Miller, A.; Gandhi, S.; Ford, L.A.; Vigil, C.E.; Griffiths, E.A.; Thompson, J.E.; Wetzler, M.; Wang, E.S. Comparison
of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients >/=60 years old.
Am. J. Hematol. 2015, 90, 639–646. [CrossRef] [PubMed]
Stein, E.M.; Dinardo, C.D.; Pollyea, D.A.; Fathi, A.T.; Roboz, G.J.; Altman, J.K.; Stone, R.M.; DeAngelo, D.J.; Levine, R.L.;
Flinn, I.W.; et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood 2017, 130, 722–731. [CrossRef]

